Clinical Milestone: Nature Medicine Publishes Results of First-in-Human "Molecular Photoswitch" Study to Restore Vision

Kiora Pharmaceuticals' Phase 1 study shows KIO-301 molecular photoswitch is safe and feasible for restoring light perception in retinitis pigmentosa patients.

By: AXL Media

Published: Apr 14, 2026, 11:41 AM EDT

Source: Information for this report was sourced from EurekAlert!

A New Frontier in Retinal Restoration

The pursuit of a cure for inherited blindness has reached a significant peer-reviewed milestone with the publication of Phase 1 clinical data for KIO-301 in Nature Medicine. The study, conducted by Kiora Pharmaceuticals, investigated the use of a "molecular photoswitch" designed to restore light sensitivity in patients with late-stage retinitis pigmentosa (RP). Unlike gene therapies that target specific mutations, this small-molecule approach aims to be "mutation-agnostic," meaning it could potentially benefit any patient with advanced retinal degeneration regardless of the underlying genetic cause.

Mechanism of the Molecular Photoswitch

KIO-301 is an innovative small molecule containing a light-reactive azobenzene. In a healthy eye, photoreceptors (rods and cones) convert light into electrical signals. In patients with RP, these cells degenerate, leading to blindness. KIO-301 is designed to enter retinal ganglion cells—neurons located "downstream" from the damaged photoreceptors—and install light-sensitive "switches" onto their ion channels. This allows the ganglion cells themselves to react to light, effectively hijacking the eye's neural circuitry to send visual signals to the brain.

Phase 1 Safety and Feasibility Results

The ABACUS-1 trial was an open-label, dose-escalation study involving six participants with minimal to no light perception. The primary goal was to assess the safety of delivering the drug via intravitreal injection. According to the published findings, the trial met its primary safety endpoints with no serious adverse events, intraocular inflammation, or structural changes to the retina observed over the 30-day monitoring period. Secondary exploratory data also noted light-induced changes in brain activity, as measured by functional MRI (fMRI), suggesting that the drug successfully initiated signaling to the visual cortex.